Barclays PLC Purchases 139,617 Shares of Veru Inc. (NASDAQ:VERU)

Barclays PLC grew its position in Veru Inc. (NASDAQ:VERU) by 309.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 184,777 shares of the company’s stock after purchasing an additional 139,617 shares during the quarter. Barclays PLC owned approximately 0.13% of Veru worth $142,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Bank of New York Mellon Corp grew its stake in shares of Veru by 1,718.2% in the second quarter. Bank of New York Mellon Corp now owns 443,782 shares of the company’s stock worth $373,000 after acquiring an additional 419,374 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Veru by 3,994.8% in the second quarter. Rhumbline Advisers now owns 113,632 shares of the company’s stock worth $96,000 after acquiring an additional 110,857 shares during the last quarter. Blair William & Co. IL grew its stake in shares of Veru by 6.1% in the second quarter. Blair William & Co. IL now owns 350,000 shares of the company’s stock worth $294,000 after acquiring an additional 20,000 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Veru in the second quarter worth $161,000. Finally, Perceptive Advisors LLC grew its stake in shares of Veru by 26.5% in the second quarter. Perceptive Advisors LLC now owns 7,063,277 shares of the company’s stock worth $5,942,000 after acquiring an additional 1,478,578 shares during the last quarter. Institutional investors own 47.16% of the company’s stock.

Veru Stock Down 4.6 %

NASDAQ:VERU opened at $1.04 on Thursday. Veru Inc. has a twelve month low of $0.36 and a twelve month high of $1.92. The business has a 50 day moving average price of $0.71 and a two-hundred day moving average price of $0.80. The company has a market cap of $152.24 million, a P/E ratio of -3.71 and a beta of -0.53.

Veru (NASDAQ:VERU) last released its earnings results on Monday, December 16th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. Veru had a negative net margin of 223.85% and a negative return on equity of 92.88%. As a group, analysts anticipate that Veru Inc. will post -0.26 earnings per share for the current fiscal year.

Analyst Ratings Changes

VERU has been the topic of a number of recent research reports. Oppenheimer reiterated an “outperform” rating and set a $5.00 price target on shares of Veru in a research note on Tuesday, November 5th. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Veru in a research note on Thursday, January 2nd.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.